Education
About Us
Working with TipRanks
Follow Us
Merus NV (DE:2GH)
FRANKFURT:2GH
2GH Analyst Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2GH Stock 12 Month Forecast
Average Price Target
€78.39
▲(140.48% Upside)
| Highest Price Target€96.44 | Average Price Target€78.39 | Lowest Price Target€58.74 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
Reiterated
04/08/25
LifeSci Capital
Reiterated
04/07/25
Citi
Reiterated
03/20/25
Bank of America Securities
Reiterated
03/07/25
Stifel Nicolaus
Reiterated
03/06/25
Piper Sandler
Reiterated
03/03/25
Canaccord Genuity
Reiterated
03/03/25
H.C. Wainwright
Reiterated
02/28/25
Truist Financial
Reiterated
02/28/25
William Blair
Reiterated
02/28/25
BMO Capital
€84.03→€84.91
Buy
160.47%
Upside
Reiterated
02/27/25
Merus's Strategic Advancements and Clinical Progress Justify Buy Rating
Guggenheim
€96.41
Buy
195.74%
Upside
Reiterated
02/27/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Krystal Biotech (NASDAQ: KRYS) and Treace Medical Concepts (NASDAQ: TMCI)
Wells Fargo
€80.49
Buy
146.90%
Upside
Reiterated
02/27/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Xencor (NASDAQ: XNCR) and Merus (NASDAQ: MRUS)
Leerink Partners
€77.84
Buy
138.76%
Upside
Reiterated
02/27/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Merus (NASDAQ: MRUS) and Agilent (NYSE: A)
TD Cowen
―
Buy
―
Reiterated
02/27/25
Merus's Promising Clinical Developments and Regulatory Progress Justify Buy Rating
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
Reiterated
04/08/25
LifeSci Capital
Reiterated
04/07/25
Citi
Reiterated
03/20/25
Bank of America Securities
Reiterated
03/07/25
Stifel Nicolaus
Reiterated
03/06/25
Piper Sandler
Reiterated
03/03/25
Canaccord Genuity
Reiterated
03/03/25
H.C. Wainwright
Reiterated
02/28/25
Truist Financial
Reiterated
02/28/25
William Blair
Reiterated
02/28/25
BMO Capital
€84.03→€84.91
Buy
160.47%
Upside
Reiterated
02/27/25
Merus's Strategic Advancements and Clinical Progress Justify Buy Rating
Guggenheim
€96.41
Buy
195.74%
Upside
Reiterated
02/27/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Krystal Biotech (NASDAQ: KRYS) and Treace Medical Concepts (NASDAQ: TMCI)
Wells Fargo
€80.49
Buy
146.90%
Upside
Reiterated
02/27/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Xencor (NASDAQ: XNCR) and Merus (NASDAQ: MRUS)
Leerink Partners
€77.84
Buy
138.76%
Upside
Reiterated
02/27/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Merus (NASDAQ: MRUS) and Agilent (NYSE: A)
TD Cowen
―
Buy
―
Reiterated
02/27/25
Merus's Promising Clinical Developments and Regulatory Progress Justify Buy Rating
Best Analysts Covering Merus
Which Analyst Should I Follow If I Want to Buy DE:2GH and Sell After:
1 Month
xxx
Success Rate
9/16 ratings generated profit
Average Return
-0.35%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of -0.35% per trade.
3 Months
xxx
Success Rate
8/11 ratings generated profit
Average Return
+18.27%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +18.27% per trade.
1 Year
Success Rate
6/12 ratings generated profit
Average Return
+57.72%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +57.72% per trade.
2 Years
xxx
Success Rate
17/26 ratings generated profit
Average Return
+71.00%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 65.38% of your transactions generating a profit, with an average return of +71.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
2GH Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
22
19
27
20
21
Buy
17
15
11
4
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
34
38
24
24
Each month's total comprises the sum of three months' worth of ratings.
2GH Financial Forecast
2GH Stock Forecast FAQ
What is DE:2GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Merus NV’s 12-month average price target is 78.39.
What is DE:2GH’s upside potential, based on the analysts’ average price target?
Merus NV has 140.48% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Merus NV a Buy, Sell or Hold?
Merus NV has a consensus rating of Strong Buy, which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
What is Merus NV’s share price target?
The average share price target for Merus NV is 78.39. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €96.44 ,and the lowest forecast is €58.74. The average share price target represents 140.48% Increase from the current price of €32.6.
The highest analyst share price target is €96.44 ,and the lowest forecast is €58.74. The average share price target represents 140.48% Increase from the current price of €32.6.
What do analysts say about Merus NV?
Merus NV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of Merus NV?
To buy shares of DE:2GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.